Welcome to BioSeeker Group!

Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 5034
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies.

    To find out more about Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer
The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451
7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699
8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039
10 Disclaimer 1040
11 Drug Index 1041
12 Company Index 1050
Figures: Includes 6 Figures
Tables: Includes 242 Tables
Total Number of Pages: 1,056

Part II: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Advanced Life Sciences
AEgera
AEterna Zentaris
Affibody
Affimed Therapeutics
Affitech
AGY Therapeutics
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
ALSP
Altor BioScience
Ambrilia Biopharma
Amgen
Amorfix Life Sciences
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
Antisense Pharma
Antisoma
Aphios
Apogenix
ApopLogic Pharmaceuticals
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bayer
Berkeley Lab
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biocompatibles
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
Biomas
Bionovo
BioNumerik
Biosceptre
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Can-Fite BioPharma
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cellmid
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
Cephalon
CG Therapeutics
ChemGenex Pharmaceuticals
ChemoCentryx
Chlorogen
Choongwae
Chroma Therapeutics
Circadian Technologies
Clavis Pharma
Cleveland BioLabs
CombinatoRx
Coronado Biosciences
Cosmo Pharmaceuticals
Critical Outcome Technologies
CSL
CuraGen
CureTech
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Deciphera Pharmaceuticals
Dendreon
DeveloGen
DiaMedica
Dompe
Dr Reddy’s
Dyax
Dynavax Technologies
EGEN Inc
Eisai
Elan
Eleos
Eli Lilly
Emergent BioSolutions
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Ergon Pharmaceuticals
Erimos
Etubics
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
FasTrack Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Genta
GenVec
Genzyme
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlycoGenesys
Glycotope
GPC Biotech
Gradalis
Green Cross
Harbor BioSciences
Hawthorn Pharmaceuticals
Heidelberg Pharma
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IDM Pharma
IkerChem
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Inovio
Insmed
Insys Therapeutics
Intracel
Intradigm
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Jennerex Biotherapeutics
Johnson & Johnson
Kaketsuken
KaloBios
Kalypsys
Keryx Biopharmaceuticals
Kiadis
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Labopharm
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MacroGenics
MAT Biopharma
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Mycenax
Nektar Therapeutics
Neovacs
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neuren
NicOx
NIH
Nippon Kayaku
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
Nycomed Pharma
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncozyme Pharma
Onyvax
Orca Therapeutics
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmaclon
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Plexxikon
POZEN
Prima Biomed
Pro-Pharmaceuticals
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
Protherics
QLT
Ramot
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
Rigel
Rosetta Genomics
Sanofi
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
Scancell
Seattle Genetics
Semafore Pharmaceuticals
Senesco Technologies
Shanghai CP Guojian
Shenogen
Shire
Sigma-Tau
Simcere Pharmaceuticals
Spirogen
SRI International
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Supratek Pharma
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Symphogen
Synageva BioPharma
SynDevRx
SynerGene Therapeutics
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Targa Therapeutics
Targepeutics
Tau Therapeutics
Taxolog
TeGenero
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
The Genetics Company
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
UMN Pharma
United Therapeutics
Vaccinex
Wakunaga
ValiRx
VasGene Therapeutics
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
VioQuest
VioQuest Pharmaceuticals
Viragen
Viralytics
ViroTarg
Viventia Biotech
VM Discovery
Wyeth
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
Zenotech
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
adecatumumab
AEG-35156
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
alvocidib
amatuximab
AME-133
AMG-386
Angiozyme
APG-101
ARQ-197
AS-101
AS-1411
AV-299
bardoxolone methyl
belimumab
belinostat
bevacizumab
BHQ880
blinatumomab
BMS-663513
BMS-936558
bortezomib
bosutinib
brentuximab vedotin
brivanib alaninate
BT-062
BZL-101
canfosfamide hydrochloride
capecitabine
carlumab
catumaxomab
CDX-1307
CDX-1401
cediranib
cenersen
cetuximab
cintredekin besudotox
cixutumumab
CMAB302
CMAB304
conatumumab
crolibulin
CT-011
dalotuzumab
daratumumab
denosumab
dinaciclib
doxifluridine
dulanermin
elotuzumab
EMD-273063
EMD525797
enzastaurin hydrochloride
epratuzumab
epratuzumab-Y90
ertumaxomab
everolimus
farletuzumab
figitumumab
fosbretabulin tromethamine
fresolimumab
galiximab
ganitumab
gataparsen
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GS-6634
GT-111
HE-3235
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
idronoxil
imatinib mesilate
imetelstat
inotuzumab ozogamicin
interferon gamma
intetumumab
IPH-2102
ipilimumab
iratumumab
irinotecan bead
irinotecan hydrochloride
kahalalide F
L19-TNFalpha
lestaurtinib
lintuzumab
LIP-131I
litronesib
lonaprisan
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MEDI-551
MEDI-573
MGN-1703
milatuzumab
milatuzumab-doxorubicin
MKC-1
MM-111
MM-121
mocetinostat
mogamulizumab
MOR202
MOR208
MORAb-004
motexafin gadolinium
moxetumomab pasudotox
naptumomab estafenatox
natalizumab
navitoclax
necitumumab
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
ofatumumab
olaratumab
ON-01910
onartuzumab
Oncohist
Onyvax-105
oregovomab
panitumumab
panobinostat
PAT-SC1
PBI-1402
PCI-24781
perifosine
pertuzumab
PF-4856884
plitidepsin
PX-12
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
raltitrexed
ramucirumab
Reditux
regorafenib
retaspimycin
RG-7160
rilotumumab
rituximab
robatumumab
romiplostim
sagopilone
samalizumab
SAR-3419
seliciclib
siltuximab
sotatercept
SPC-2996
ß-lapachone
SU-6668
Sym-004
tegafur + uracil
tegafur + uracil + leucovorin
Tenarad
terameprocol
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
tocilizumab
TRC-105
tremelimumab
triciribine phosphate
TRU-016
TS-1
tucotuzumab celmoleukin
U3-1287
Ublituximab
veltuzumab
volasertib
volociximab
vosaroxin
XL-147
XL-647
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies.
    To find out more about Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Melanoma, Apoptosis and Angiogenesis
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis. Learn More


Triple Analysis: Melanoma, Prostate Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Melanoma and Prostate Cancer and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Oncology' category:


Target Atlas in Myelodysplastic Syndrome: A Competitive Outlook
System Requirements - Operating system: Windows (2000/XP/Vista/7/8/10) and Mac OS X 10.6 (Snow Leopard) and OS X 10.7 (Lion)
- Browser Application (Internet Explorer)
- Internet access (to access related internet resources)
Learn More


Colorectal Cancer: Analytical Tool
This Analytical Tool transforms your computer’s desktop into a high capacity workbench within the area of colorectal cancer. It supports you in making reports, presentations and preparing conference attendance and it is all done via an easy to use ’point and click’ interface. Learn More